Boston Therapeutics, Inc.
BTHE · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | -0.00 | -0.01 |
| FCF Yield | -49.71% | -12.46% | -2.61% | -12.23% |
| EV / EBITDA | -0.00 | -2.48 | -0.57 | -24.67 |
| Quality | ||||
| ROIC | 1,139.13% | -117.32% | 31.69% | 7.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -1,434.80% |
| Cash Conversion Ratio | 0.00 | 0.32 | 0.01 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -61.87% | -48.19% | -38.29% | -33.48% |
| Free Cash Flow Growth | -299.11% | -532.92% | -32.79% | 19.62% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.36 | -0.08 | -20.05 |
| Interest Coverage | 0.00 | -4.03 | -26.98 | -2.38 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 7.51 |
| Cash Conversion Cycle | 0.00 | 0.00 | -3,209.24 | -2,846.80 |